Changes in c‐erbB‐2 Immunoexpression in Feline Endometrial Adenocarcinomas

Saraiva, Aratã Andrade; Payan-Carreira, Rita; Gärtner, Fátima; Faria, Fátima; Lourenço, Luís Carvalho; Pires, M.A.

doi:10.1111/rda.12642

Cited by 3 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The veterinary literature on ErbB family gene expression is extensive. The expression of epidermal growth factor receptors has been reported in several cancer types, including canine mammary carcinoma [25], gastric epithelial tumors [36], urothelial neoplasms [37,38], ovarian tumors [39], osteosarcoma [40], lung cancer [41], anal sac gland tumors [42] and feline mammary tumors [43,44], endometrial tumors [45], and pulmonary carcinoma [46]. Despite melanoma being among the first tumors in which EGFR is suggested to be a metastatic marker [47], little is known about ErbB receptors in this cancer, and the literature about this issue is sometimes controversial.…”

Section: Discussionmentioning

confidence: 99%

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas

Parisi,

Aurisicchio,

Pecorari

et al. 2024

Animals

View full text Add to dashboard Cite

Canine melanoma is a malignant and aggressive neoplasm showing clinical, histological, and molecular features similar to the human counterpart. In human medicine, epidermal growth factor receptors (EGFRs) have already been suggested as prognostic markers and potential therapeutic targets in cutaneous melanoma. The aim of this study was to evaluate the expression of HER-2 and HER-3 in canine melanomas by immunohistochemistry and correlate their expression to the clinicopathological parameters of the examined tumors. Thirty-seven canine melanoma samples were recruited. Data regarding signalment and clinical parameters were also collected. The population was composed of 18 cutaneous, 16 oral/mucosal, and three digital/foot pad melanomas. Histopathological investigations were carried out to analyze histological type, ulceration, and mitotic count. On each sample, immunohistochemistry was performed using an anti-Melan-A or anti-Melanoma antigen, i.e., anti-HER-2 and anti-HER-3 antibodies. HER-2 and HER-3 positivity were classified using already established scoring criteria and a statistical analysis was carried out. The results highlighted that HER-2 expression was observed in 48.6% of the samples and HER-3 expression in 18.9%. The highest HER 2 score (3+) was recorded in 16.2% of the samples, while the coexpression of the two receptors was detected in 13.5% of the samples. A statistically significant association (p < 0.05) was observed between the expression of HER-2 and HER-3 and the presence of ulceration in oromucosal tumors. This work confirms the expression of HER-2 and HER-3 in canine melanomas and suggests a putative association with negative prognostic parameters. Further studies are necessary to strengthen these data by increasing the samples size and combining pathological examinations with molecular biology in the investigation of EGFR family receptors.

show abstract

Section: Discussionmentioning

confidence: 99%

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas

Parisi,

Aurisicchio,

Pecorari

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

“…Mammary gland [44,45] Endometrium [46,47] IHC Uterine wall glandular epithelium [47] Gastric mucosal surface cells and parietal cells (in Helicobacter heilmanii colonization) [48] RET Developing gut [49] Developing pancreas [50] IHC…”

Section: Tyrosine Kinase Tissue Methodsmentioning

confidence: 99%

“…Apart from the above-mentioned tumors, TK expression and/or TKI treatment has been investigated in feline pulmonary carcinomas [146,147], endometrial adenocarcinoma [46], feline histiocytic disorders [54], renal cell carcinoma [58,59,148,149], iris melanomas [150], granulosa cell tumors [56], adrenal cortex carcinoma [56], thyroid gland carcinoma [56], Non-Hodgkin's lymphoma [56], leiomyosarcoma of the gastrointestinal tract [140,151,152], osteosarcoma [57], oligodendrogliomas and subependymomas [153], colonic malignant peripheral nerve sheath tumors [154], gemistocytic astrocytoma [155], Merkel cell carcinoma [156], pancreatic adenocarcinoma [157,158], chemodectoma [159], tracheal adenocarcinoma [160] and hypereosinophilic syndrome [161].…”

Section: Other Malignanciesmentioning

confidence: 99%

“…However, no correlation was found between HER2 expression and various pathological features, such as nuclear atypia, mitotic number, and myometrium, serosa and vascular invasion. As a result, the impact of HER2 on progression and prognosis of FEA has been called into question [46]. On the other hand, the immunoexpression of HER2 was also reported in the hyperplastic endometrial polyps of two cats with a cystic endometrial hyperplasia-pyometra complex, suggesting its potential involvement in the pathogenesis of endometrial hyperplasia [47,164].…”

Section: Other Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions

Žagar,

Schmidt

2023

Animals

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) have become invaluable in the treatment of human and canine malignancies, but their role in feline oncology is less defined. While toceranib phosphate and masitinib mesylate are licensed for use in dogs, no TKI is yet approved for cats. This review systematically maps the research conducted on the expression of tyrosine kinases in neoplastic and non-neoplastic domestic feline tissues, as well as the in vitro/in vivo use of TKIs in domestic cats. We identify and discuss knowledge gaps and speculate on the further research and potential indications for TKI use in cats. A comprehensive search of three electronic databases and relevant paper reference lists identified 139 studies meeting the inclusion criteria. The most commonly identified tumors were mast cell tumors (MCTs), mammary and squamous cell carcinomas and injection-site sarcomas. Based on the current literature, toceranib phosphate appears to be the most efficacious TKI in cats, especially against MCTs. Exploring the clinical use of TKIs in mammary carcinomas holds promise. Despite the progress, currently, the evidence falls short, underscoring the need for further research to discover new indications in feline oncology and to bridge the knowledge gaps between human and feline medicine.

show abstract

“…The involvement of the EGF receptor in embryonic development and tissue maturation has also been reported using embryonic cell lines and EGFR-knockout mice models [4][5][6][7][8], which indicates its essential role in the vital activity of pluripotent stem cells. Expression of this prototypical tyrosine kinase receptor and some of its ligands was also reported in MSCs of various tissue origin, including endometrium [9][10][11][12]. Studies on the EGFR role in endometrial MSC (enMSC) provide several lines of evidence of its participation in the regulation of both proliferation and differentiation into decidual cells that are essential for embryo implantation.…”

Section: Introductionmentioning

confidence: 97%

EGF, TGF-α and Amphiregulin Differently Regulate Endometrium-Derived Mesenchymal Stromal/Stem Cells

Kamentseva,

Kharchenko,

Gabdrahmanova

et al. 2023

IJMS

View full text Add to dashboard Cite

The prototypical receptor tyrosine kinase epidermal growth factor receptor (EGFR) is regulated by a set of its ligands, which determines the specificity of signaling and intracellular fate of the receptor. The EGFR signaling system is well characterized in immortalized cell lines such as HeLa derived from tumor tissues, but much less is known about EGFR function in untransformed multipotent stromal/stem cells (MSCs). We compared the effect of epidermal growth factor (EGF), transforming growth factor-α (TGF-α) and amphiregulin (AREG) on physiological responses in endometrial MSCs (enMSC) and HeLa cells. In addition, using Western blotting and confocal microscopy, we studied the internalization and degradation of EGFR stimulated by the three ligands in these cell lines. We demonstrated that unlike HeLa, EGF and TGF-α, but not AREG, stimulated enMSC proliferation and prevented decidual differentiation in an EGFR-dependent manner. In HeLa cells, EGF targeted EGFR for degradation, while TGF-α stimulated its recycling. Surprisingly, in enMSC, both ligands caused EGFR degradation. In both cell lines, AREG-EGFR internalization was not registered. In HeLa cells, EGFR was degraded within 2 h, restoring its level in 24 h, while in enMSC, degradation took more than 4–8 h, and the low EGFR level persisted for several days. This indicates that EGFR homeostasis in MSCs may differ significantly from that in immortalized cell lines.

show abstract

Changes in c‐erbB‐2 Immunoexpression in Feline Endometrial Adenocarcinomas

Cited by 3 publications

References 42 publications

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions

EGF, TGF-α and Amphiregulin Differently Regulate Endometrium-Derived Mesenchymal Stromal/Stem Cells

Contact Info

Product

Resources

About